

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis ID6246

Provisional Stakeholder List

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Amylyx Pharmaceuticals (sodium phenylbutyrate–ursodoxicoltaurine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Beacon • Brain and Spine Foundation • Brain Charity • Gene People • Genetic Alliance UK • Motor Neurone Disease Association • My Name’s5 Doddie Foundation • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Neuroscience Nurses • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • British Society of Physical and Rehabilitation Medicine • British Thoracic Society • Chartered Society of Physiotherapy • College of Occupational Therapists • Institute of Neurology • Institute of Psychiatry • National Neuroscience Advisory Group • Primary Care Neurology Society | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Glenmark Pharmaceuticals Europe Ltd (Riluzole) • Martindale Pharma (Riluzole) • Ranbaxy UK Limited (Riluzole) • Sanofi (Riluzole) • Zambon UK Limited (Riluzole) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Cochrane Airways group • Cochrane Cystic Fibrosis and Genetic |

Provisional stakeholder list for the evaluation of sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis ID6246

Issue date: June 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal College of Speech and Language Therapists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • National Hospital for Neurology and Neurosurgery • NHS England | <p>Disorders Group</p> <ul style="list-style-type: none"> • Cochrane Movement Disorders Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Oxford Motor Neuron Disease Centre • UCL Institute of Neurology <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.